Марказий Осиё эндокринологик журнали 6-jild 2-son (2026)
TREATMENT OF CHRONIC HEART FAILURE WITH A LOW EJECTION FRACTION WITH SACUBITRIL/VALSARTAN (SAVESTO) ON THE BACKGROUND OF DIABETES MELLITUS TYPE 2
Файзуллаев Бахром Рустамович, Исломов Иномжон Исломович, Хусаинов Адхам Шухратович, Норматова Умида Юлдашевна
Annotatsiya
Relevance. This article analyzes the process of treating patients with CHF and CHF with a low ejection fraction against the background of type 2 diabetes mellitus. Heart failure with reduced ejection fraction (HFrEF) remains one of the most significant medical and social problems, particularly when combined with type 2 diabetes mellitus (T2DM). In 2016, the original angiotensin receptor–neprilysin inhibitor (ARNI), sacubitril/valsartan, was introduced under the trade name Yuperio and demonstrated a convincing reduction in hospitalizations and mortality among this patient population. Subsequently, a generic version — Savesto — became available, containing the same combination of neprilysin inhibitor and angiotensin II receptor blocker. The purpose of this study was to evaluate whether Savesto (szcubitril/valsartan) is non-inferior in terms of efficacy and safety in patients with HFrEF and T2DM, including those who were switched from the branded medication. Materials and methods. A total of 57 patients hospitalized with chronic heart failure and acute decompensation on the background of T2DM were enrolled. Treatment with Savesto resulted in clinical improvement, reduction in NYHA functional class, decrease in NT-proBNP levels, favorable dynamics of laboratory parameters, and positive echocardiographic changes. Although some patients experienced symptomatic arterial hypotension and a decline in eGFR, overall tolerability was acceptable, and the safety profile was comparable to that of Entresto. In conclusion, the obtained results indicate that the use of Savesto can be considered as a rational and affordable alternative to the original drug in patients with heart failure with reduced ejection fraction and type 2 diabetes mellitus, while maintaining proven therapeutic value and safety.
сердечная недостаточность, острая декомпенсация сердечной недостаточности, сакубитрил/валсартан (Савесто), сахарный диабет 2-типа, хроническая почечная недостаточность, низкая фракция выбросаheart failure, CHF, acute decompensation of heart failure, sacubitril/valsartan (Savesto), type 2 diabetes mellitus, chronic renal failure, low ejection fractionyurak etishmovchiligi, yurak etishmovchiligining o'tkir dekompensatsiyasi, sakubitril/valsartan (Savesto), 2-toifa diabet, surunkali buyrak etishmovchiligi, past otish fraktsiyasi
Metadata manbasi: jurnal OAI-PMH arxivi · Sindex toʻliq matnni saqlamaydi, manbaga havola beradi.